DDInter492 DDInter1676
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Deflazacort {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esterified estrogens
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Cinoxacin
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Deflazacort may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Deflazacort may lead to a major life threatening interaction when taken with Cinoxacin
Deflazacort may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live